LACTOLOGY FOUNDATION

Drugs in ATC class A02BB are prostaglandin analogues (mainly misoprostol and enprostil) used for prevention and treatment of peptic ulcer disease and related acid disorders, with notable systemic toxicity and generally low lactation risk at usual doses. Below is an English concise toxico‑lactological monograph suitable as web page content.

Pharmacological class and ATC scope

• ATC group: A02B – Drugs for peptic ulcer and gastro‑oesophageal reflux disease (GORD). Peptic ulcers in this context include oesophageal, gastric and duodenal ulcers.
• Subgroup: A02BB – Prostaglandins.
• Individual substances: A02BB01 misoprostol; A02BB02 enprostil.

These agents are synthetic analogues of endogenous prostaglandins, derived from arachidonic acid, with a very short plasma half‑life due to rapid metabolism in liver, lungs, kidneys and the gastrointestinal tract.

Mechanism of action and clinical use

• Misoprostol and enprostil are analogues of prostaglandin E that stimulate mucous and bicarbonate secretion, increase mucosal blood flow and enhance epithelial restitution, thereby exerting a cytoprotective effect on the gastric and duodenal mucosa.
• They also reduce basal and stimulated gastric acid secretion by acting on specific prostaglandin receptors on parietal cells.

Main approved gastrointestinal uses include:

• Prevention and treatment of NSAID‑induced gastric and duodenal ulcers in high‑risk patients.
• Adjunctive treatment of peptic ulcer disease when acid suppression alone is insufficient or contraindicated.

Low‑dose misoprostol tablets used for obstetric indications (cervical ripening, induction of labour, termination of pregnancy) are classified elsewhere (G02AD), as these regimens exploit primarily uterotonic rather than gastroprotective effects.

General toxicological profile

Prostaglandins display what can be described as “overflowing toxicity”: the same signalling pathways that mediate physiological functions are involved in a broad spectrum of adverse reactions when the system is excessively stimulated.

• Common dose‑limiting adverse effects with oral A02BB agents are gastrointestinal: abdominal cramping, diarrhoea, nausea and vomiting; these are dose‑related and reflect stimulation of intestinal smooth muscle and secretion.
• Cardiovascular effects include vasodilation, flushing and hypotension; rarely, myocardial ischaemia can be precipitated in susceptible individuals due to hypotension or coronary steal phenomena.
• CNS effects such as headache, dizziness and malaise are reported and may be more pronounced in elderly or volume‑depleted patients.

Because of rapid systemic metabolism, many acute reactions are short‑lived, but severe toxicity may occur with overdosing or inappropriate routes of administration (e.g. high vaginal/ buccal doses used off‑label).

Reproductive toxicity and teratogenicity

Prostaglandins are deeply involved in reproductive physiology, including ovulation, implantation, cervical ripening and uterine contractility.

• Misoprostol and related prostaglandin E analogues have a well‑documented teratogenic and fetotoxic potential when used in early pregnancy without leading to complete abortion, with reports of cranial, limb and nervous system malformations.
• For this reason, A02BB drugs are contraindicated in pregnancy when used for gastroprotective indications, and strict contraception is recommended in women of childbearing potential.

When employed deliberately for induction of labour or medical termination of pregnancy (using lower‑strength formulations classified in other ATC groups), the uterotonic and cervical ripening actions are therapeutically exploited but also carry risks of uterine hyperstimulation, fetal distress, uterine rupture and postpartum haemorrhage.

Toxicological risk in special populations

• Elderly patients are more susceptible to hypotension, dehydration from diarrhoea and electrolyte disturbances; doses should be individualised and volume status monitored.
• Patients with cardiovascular disease may experience exacerbation of angina or arrhythmias in the setting of prostaglandin‑induced hypotension or reflex tachycardia.
• In hepatic or renal impairment, systemic exposure to active metabolites may increase, potentially intensifying adverse effects despite the normally short half‑life of these compounds.

Drug interactions are mainly pharmacodynamic: concomitant use with other diarrhoea‑inducing agents or antihypertensives can potentiate gastrointestinal or hypotensive reactions, and combination with anticoagulants or antiplatelets may increase bleeding risk when prostaglandins are used for obstetric procedures.

Lactation: pharmacokinetics in breast milk

Available data indicate that misoprostol and other prostaglandin E analogues pass into breast milk in very low quantities, with rapid decline in milk concentrations due to the short maternal half‑life and active metabolism.

• Misoprostol: Studies and expert reviews (including LactMed and specialist pharmacy services) show that oral doses used for medical termination or miscarriage management result in very low levels in breast milk, with estimated relative infant doses well below 10% of the maternal weight‑adjusted dose.
• Enprostil: Direct lactation data are lacking, but given its similar class, short half‑life and oral use for gastrointestinal indications, clinically significant exposure of the breastfed infant is considered unlikely at standard doses.

Because of the low levels and rapid elimination, repeated maternal dosing for ulcer prophylaxis is not expected to lead to accumulation or pharmacological effects in the breastfed infant.

Clinical lactation safety and recommended use

Current evidence and expert consensus suggest that oral misoprostol at usual therapeutic doses is compatible with breastfeeding.

• Several reviews state that no interruption of breastfeeding is necessary after misoprostol, whether used for gastrointestinal indications or as part of medical abortion or miscarriage management; LactMed notes that no special precautions are required.
• Some authors propose an optional short interruption (about 4–5 hours after an oral dose) in order to minimise any theoretical risk of diarrhoea in the infant, but this is not universally recommended and is not considered mandatory.

For enprostil, in the absence of specific data, cautious extrapolation from misoprostol and general prostaglandin pharmacology supports its use during lactation with standard doses, while monitoring the infant for gastrointestinal symptoms such as loose stools, irritability or poor feeding.

In all cases:

• Use the lowest effective dose for the shortest possible duration.
• Prefer agents with more extensive lactation safety data (e.g. proton pump inhibitors or H2‑blockers) when clinically equivalent and appropriate, reserving A02BB prostaglandins for situations where their gastroprotective profile is specifically required.

Key counselling points for breastfeeding patients

• Explain that these medicines are synthetic analogues of naturally occurring prostaglandins with very short persistence in the body and in breast milk.
• Reassure that available evidence shows very low levels in milk and no documented serious adverse effects in breastfed infants at usual doses, but advise the mother to observe the infant for diarrhoea, vomiting or unusual irritability.
• Emphasise strict avoidance in pregnancy when used for ulcer prophylaxis because of the established teratogenic and fetotoxic risk, and clarify the distinction between low‑dose obstetric regimens and higher‑dose gastroprotective use.